AAMC
REGN icon

Asset Allocation & Management Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Asset Allocation & Management Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-423
Closed -$327K – 87
2026
Q1 		$327K Buy
+423
New +$324K 0.12% 70

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCI
McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Asset Allocation & Management Company's REGN Position: Q2 2026 in Review

Asset Allocation & Management Company sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 423 shares — an estimated $327K sold.

Asset Allocation & Management Company first reported a position in REGN in Q1 2026 and held it in 1 quarter. The position peaked at $327K in Q1 2026. 518 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Asset Allocation & Management Company reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Asset Allocation & Management Company sold 423 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $327K.
  • Asset Allocation & Management Company first reported a position in Regeneron Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Asset Allocation & Management Company's Regeneron Pharmaceuticals position peaked at $327K in Q1 2026.
  • 518 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Asset Allocation & Management Company's 13F filing for Q2 2026, filed 15 Jul 2026.